Stock Events

Stock Events

OnKure Therapeutics 

$3.93
26
-$0.15-3.68% 20:00 Today
+$0.00+0%20:00After hours

Statistics

Day High
4.04
Day Low
3.78
52W High
5.38
52W Low
2.23
Volume
103,519
Avg. Volume
298,096
Mkt Cap
159.15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.38
-1.02
-0.67
-0.31
Expected EPS
-0.41
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-59.52MNet Income

Analyst Ratings

17.50Average Price Target
The highest estimate is 21.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OKUR. It's not an investment recommendation.
Schwab US Dividend Equity
3
SCHD
ExxonMobil
3
XOM
Energy Transfer
3
ET
SLB
3
SLB

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, competing in the rare disease space similar to Reneo Pharmaceuticals.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics is involved in the development of genetic medicines for rare diseases, directly competing with Reneo Pharmaceuticals' focus on rare genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, closely aligning with Reneo Pharmaceuticals' mission.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals works on RNAi therapeutics for the treatment of rare diseases, presenting a competitive approach to Reneo Pharmaceuticals' strategy.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, which places it in direct competition with Reneo Pharmaceuticals in the rare disease market.
PTC Therapeutics
PTCT
Mkt Cap5.98B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines for rare disorders, making it a competitor to Reneo Pharmaceuticals.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is focused on developing gene-based medicines for serious diseases, including rare diseases, which places it in competition with Reneo Pharmaceuticals' focus on genetic disorders.

About

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Show more...
CEO
Nicholas A. Saccomano
Employees
45
Country
United States
ISIN
US68277Q1058

Listings

XNAS
US
OKUR
BOATS
BOATS
OKUR.BOATS

0 Comments

Share your thoughts

FAQ

What is OnKure Therapeutics stock price today?▼
The current price of OKUR is $3.93 USD — it has decreased by -3.68% in the past 24 hours. Watch OnKure Therapeutics stock price performance more closely on the chart.
What is OnKure Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange OnKure Therapeutics stocks are traded under the ticker OKUR.
Is OnKure Therapeutics stock price growing?▼
OKUR stock has risen by +0.77% compared to the previous week, the month change is a -4.61% fall, over the last year OnKure Therapeutics has showed a +43.96% increase.
What is OnKure Therapeutics market cap?▼
Today OnKure Therapeutics has the market capitalization of 159.15M
When is the next OnKure Therapeutics earnings date?▼
OnKure Therapeutics is going to release the next earnings report on November 05, 2026.
What were OnKure Therapeutics earnings last quarter?▼
OKUR earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.54 USD resulting in a +42.06% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is OnKure Therapeutics revenue for the last year?▼
OnKure Therapeutics revenue for the last year amounts to 0 USD.
What is OnKure Therapeutics net income for the last year?▼
OKUR net income for the last year is -59.52M USD.
How many employees does OnKure Therapeutics have?▼
As of August 20, 2026, the company has 45 employees.
In which sector is OnKure Therapeutics located?▼
OnKure Therapeutics operates in the Health & Wellness sector.
When did OnKure Therapeutics complete a stock split?▼
The last stock split for OnKure Therapeutics was on October 07, 2024 with a ratio of 1:10.
Where is OnKure Therapeutics headquartered?▼
OnKure Therapeutics is headquartered in BOULDER, United States.